Yescarta is a chimeric antigen receptor (CAR) T-cell therapy used to treat certain types of non-Hodgkin lymphoma (NHL). It is a type of immunotherapy that uses a patient's own T-cells to fight cancer. The therapy works by genetically engineering a patient's T-cells to recognize and attack cancer cells. Yescarta is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. The Yescarta market is a rapidly growing segment of the lymphoma drugs market. It is expected to witness strong growth in the coming years due to increasing prevalence of NHL, rising awareness about CAR-T therapies, and increasing investments in research and development. Some of the key players in the Yescarta market include Gilead Sciences, Inc., Novartis AG, Kite Pharma, Inc., Juno Therapeutics, Inc., and Cellectis S.A. Show Less Read more
ASK A QUESTION
We request your telephone number so we can contact you in the event we have difficulty reaching you via email. We aim to respond to all questions on the same business day.
